Effects on platelet function of an EP3 receptor antagonist used alone and in combination with a P2Y12 antagonist both in-vitro and ex-vivo in human volunteers

Platelets

Volumn 24, Issue 5, 2013, Pages 392-400

  Fox, S C ^a   May, J A ^a   Johnson, A ^a   Hermann, D ^b   Strieter, D ^b   Hartman, D ^b   Heptinstall, S ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b The Great Lakes Drug Development Inc   (United States)

Author keywords

Aspirin; Cangrelor; Clopidogrel; DG 041; EP3 receptor antagonists; P selectin; P2Y12 receptor antagonists; Platelet aggregation; Platelet function

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 3 [1 (2,4 DICHLOROBENZYL) 5 FLUORO 3 METHYL 1H INDOL 7 YL] N [(4,5 DICHLORO 2 THIENYL)SULFONYL]ACRYLAMIDE; ACETYLSALICYLIC ACID; CANGRELOR; CLOPIDOGREL; PADGEM PROTEIN; SULPROSTONE; THROMBOXANE A2;

ARTICLE; BLEEDING TIME; CONTROLLED STUDY; CROSSOVER PROCEDURE; EX VIVO STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN TISSUE; IN VITRO STUDY; LOADING DRUG DOSE; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION;

ACRYLAMIDES; BLOOD PLATELETS; FEMALE; HUMANS; MALE; P-SELECTIN; PLATELET ACTIVATION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RECEPTORS, PROSTAGLANDIN E, EP3 SUBTYPE; RECEPTORS, PURINERGIC P2Y12; SULFONES;

EID: 84879767355     PISSN: 09537104     EISSN: 13691635     Source Type: Journal    
DOI: 10.3109/09537104.2012.704648     Document Type: Article

References (22)

1. Heptinstall S, Iyú D, Manolopoulos P, Glenn JR, White AE, Johnson A, Dovlatova N, Fox SC, May JA, Hermann D, et al. DG-041 inhibits the EP3 prostanoid receptor - A new target for inhibition of platelet function in atherothrombotic disease. Platelets 2008;19:605-613
2. Singh J, Zeller W, Zhou N, Hategen G, Mishra R, Polozov A, Yu P, Onua E, Zhang J, Zembower D, et al. Antagonists of type EP3 receptor for prostaglandin E2 are novel anti-platelet agents that do not prolong bleeding. ACS Chem Biol 2009;4:115-126
3. Fabré J-E, Gurney ME. Limitations of current therapies to prevent thrombosis: A need for novel strategies. Mol Biosyst 2010;6:305-315
4. Gross S, Tilly P, Hentsch D, Vonesch JL, Fabré JE. Vascular wallproduced prostaglandin E2 exacerbates arterial thrombosis and atherothrombosis through platelet EP3 receptors. J Exp Med 2007;204:311-320
5. Ma H, Hara A, Xiao CY, Okada Y, Takahata O, Nakaya K, Sugimoto Y, Ichikawa A, Narumiya S, Ushikubi F. Increased bleeding tendency and decreased susceptibility to thromboembolism in mice lacking the prostaglandin E receptor subtype EP(3). Circulation 2001;104:1176-1180
6. Fabré J-E, Nguyen M, Athirakul K, Coggins K, McNeish JD, Austin S, Parise LK, FitzGerald GA, Coffman TM, Koller BH. Activation of the murine EP3 receptor for PGE2 inhibits cAMP production and promotes platelet aggregation. J Clin Invest 2001;107:603-610
7. Iyú DC, Glenn JR, White AE, Johnson AJ, Fox SC, Heptinstall S. The role of prostanoid receptors in mediating the effects of PGE2 on human platelet function. Platelets 2010;21:329-342
8. Philipose S, Konya V, Sreckovic I, Marsche G, Lippe IT, Peskar BA, Heinemann A, Schuligoi R. The prostaglandin E2 receptor EP4 is expressed by human platelets and potently inhibits platelet aggregation and thrombus formation. Arterioscler Thromb Vasc Biol 2010;30:2416-2423
9. Smith JP, Haddad EV, Downey JD, Breyer RM, Boutard O. PGE2 decreases reactivity of human platelets by activating EP2 and EP4. Thromb Res 2010;126:e33-e29
10. Kuriyama S, Kashiwagi H, Yuhki K, Kojima F, Yamada T, Fujino T, Hara A, Takayama K, Maruyama T, Yoshida A, et al. Selective activation of the prostaglandin E2 receptor subtype EP2 or EP4 leads to inhibition of platelet aggregation. Thromb Haemost 2010;104:796-803
11. Schober LJ, Khandoga AL, Penz SM, Siess W. The EP3 agonist sulprostone but not prostaglandin E2 potentiates platelet aggregation in human blood. Thromb Haemost 2010;103: 1268-1269
12. Dovlatova N, Wijeyeratne YD, Fox SC, Manolopoulos P, Johnson AJ, White AE, Latif ML, Ralevic V, Heptinstall S. Detection of P2Y(14) protein in platelets and investigation of the role of P2Y(14) in platelet function in comparison with the EP(3) receptor. Thromb Haemost 2008;100:261-270
13. Janzarik H, Heinrich D, Bödeker RH, Lasch HG. ''Haemostasis timé', a modified bleeding time test and its comparison with the Duke and Ivy/template bleeding times. II. Application in bleeding disorders. Blut 1988;57:111-116
14. May JA, Heptinstall S, Fox SC. Stabilisation of blood cell conjugates. International patent application number PCT/GB2009/050482, University of Nottingham, priority date 09/05/08
15. Fox SC, May JA, Heptinstall S. Stabilisation of biological cell markers. International patent application number PCT/GB2008/ 050169, University of Nottingham, priority date 08/03/07
16. Fox SC, Sasae R, Janson S, May JA, Heptinstall S. Quantitation of platelet aggregation and microaggregate formation in whole blood by flow cytometry. Platelets 2004;15:85-93
17. Fox SC, May JA, Shah A, Neubert U, Heptinstall S. Measurement of platelet P-selectin for remote testing of platelet function during treatment with clopidogrel and/or aspirin. Platelets 2009;20: 250-259
18. Harrison P. Assessment of platelet function in the laboratory. Hämostaseologie 2009;1:25-31
19. Nylander S, Johansson K, Van Giezen JJ, Lindahl TL. Evaluation of platelet function, a method comparison. Platelets 2006; 17:49-55
20. Storey RF, Judge HM, Wilcox RG, Heptinstall S. Inhibition of ADP-induced P-selectin expression and platelet-leukocyte conjugate formation by clopidogrel and the P2Y12 receptor antagonist AR-C69931MX but not aspirin. Thromb Haemost 2002;88:488-494
21. Dovlatova NL, Jakubowski JA, Sugidachi A, Heptinstall S. The reversible P2Y12 antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function. J Thromb Haemost 2008;6:1153-1159
22. Judge HM, Buckland RJ, Sugidachi A, Jakubowski JA, Storey RF. Relationship between degree of P2Y12 receptor blockade and inhibition of P2Y12-mediated platelet function. Thromb Haemost 2010;103:1210-1217